Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors

https://doi.org/10.1016/j.bmcl.2009.02.087Get rights and content

Abstract

Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid).

Graphical abstract

Starting from quinazoline 3a, we identified 3d a potent and selective ALK5 inhibitor over p38MAP kinase suitable for oral administration.

  1. Download : Download full-size image

Section snippets

Acknowledgements

We acknowledge Géraldine Poulain and Christelle Sury-Martin for their contribution to the synthesis of these compounds, and the DMPK team for performing the pharmacokinetic study.

References and notes (12)

  • J. Massague et al.

    Cell

    (2000)
    W.A. Border et al.

    N. Eng. J. Med.

    (1994)
    G.C. Blobe et al.

    N. Eng. J. Med.

    (2000)
  • F. Gellibert et al.

    J. Med. Chem.

    (2004)
    F. Gellibert

    J. Med. Chem.

    (2006)
    S.D. Byfield et al.

    Mol. Pharmacol.

    (2004)
    J.S. Sawyer

    Bioorg. Med. Chem. Lett.

    (2004)
    (e)Munchhof, M. J. WO...
  • A. Roberts et al.

    Oncogene

    (2005)
    M. Lahn et al.

    Exp. Opin. Invest. Drugs

    (2005)
    N. Dumont et al.

    Cancer Cell

    (2003)
  • R. Derynck et al.

    Cell

    (1998)
There are more references available in the full text version of this article.

Cited by (68)

View all citing articles on Scopus
View full text